The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Chronic TGF-β exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to bitopic mTOR inhibition
Open accessAbstract
Inhibiting mTOR may reverse TGF-β–induced metastatic traits and drug resistance in carcinoma cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular mechanisms of epithelial–mesenchymal transition
Lamouille, S., Xu, J., & Derynck, R. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3758 · Cited by 8,091 · cited 2×
“As epithelial cells progress through EMT, they lose epithelial cell-cell contacts and apical-basal polarity, reorganize their cytoskeleton, and reprogram gene expression to enable, among many changes, increased deposition of extracellular matrix components and matrix metalloproteases ( 6 ).”
Self-citationmTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555
Nieto, M. A., Huang, R. Y.-J., Jackson, R. A., & Thiery, J. P. (2016) · Cell · doi:10.1016/j.cell.2016.06.028 · Cited by 4,492
Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Shibue, T., & Weinberg, R. A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.44 · Cited by 2,539 · cited 3×
“Partial or complete EMT allows for cancer cell migration and invasion, enabling cancerdissemination ( 43 ),and islinkedto CSC generation and decreased anticancer drug sensitivity ( 5 , 8 ).”
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
SPECIFICITY AND VERSATILITY IN TGF-β SIGNALING THROUGH SMADS
Feng, X.-H., & Derynck, R. (2005) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.21.022404.142018 · Cited by 1,869
Self-citationFischer, K. R., Durrans, A., Lee, S., Sheng, J., Li, F., Wong, S. T. C., Choi, H., El Rayes, T., Ryu, S., Troeger, J., et al. (2015) · Nature · doi:10.1038/nature15748 · Cited by 1,791
The translational landscape of mTOR signalling steers cancer initiation and metastasis
Hsieh, A. C., Liu, Y., Edlind, M. P., Ingolia, N. T., Janes, M. R., Sher, A., Shi, E. Y., Stumpf, C. R., Christensen, C., Bonham, M. J., et al. (2012) · Nature · doi:10.1038/nature10912 · Cited by 1,313 · cited 1×
“Among many processes driven by mTOR, phosphorylation of 4EBP1 that leads to translational initiation has been suggested to be critical in tumorigenesis (31, 54, 55).”
Self-citationTargeting KRAS mutant cancers with a covalent G12C-specific inhibitor
Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172 · cited 1×
“Rather, as has been established, colony formation in soft agar reflects increased anchorage independence and anchorageindependent survival and predicts in vivo tumorigenesis (28).”
Cited by
TGFβ biology in cancer progression and immunotherapy
Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944
Self-citationTargeting mTOR for cancer therapy
Hua, H., Kong, Q., Zhang, H., Wang, J., Luo, T., & Jiang, Y. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0754-1 · Cited by 899
TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis—Updated 2019
Dewidar, B., Meyer, C., Dooley, S., & Meindl-Beinker, A. N. (2019) · Cells · doi:10.3390/cells8111419 · Cited by 837
PI3K inhibitors are finally coming of age
Vanhaesebroeck, B., Perry, M. W. D., Brown, J. R., André, F., & Okkenhaug, K. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00209-1 · Cited by 476
Cancer stem cell (CSC) resistance drivers
Najafi, M., Mortezaee, K., & Majidpoor, J. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116781 · Cited by 466
EMT and Cancer: More Than Meets the Eye
Derynck, R., & Weinberg, R. A. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.04.026 · Cited by 313
“Prolonged exposure of cultured epithelial and carcinoma cells to TGF-β also yields cells that reside stably in a mesenchymal phenotype, even after TGF-β is removed (Katsuno et al., 2019).”
BackgroundInfluentialSelf-citationTumor cell plasticity in targeted therapy-induced resistance: Mechanisms and new strategies
Shi, Z.-D., Pang, K., Wu, Z.-X., Dong, Y., Hao, L., Qin, J.-X., Wang, W., Chen, Z.-S., & Han, C.-H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01383-x · Cited by 256
“found that upon TGF-β removal, mesenchymal cells revert to an epithelial cell phenotype.(200) Moreover, prolonged TGF-β exposure promotes a stable EMT process in cancer cells, which is accompanied by increased tumor stemness and cancer drug resistance.”
BackgroundEpithelial plasticity, epithelial-mesenchymal transition, and the TGF-β family
Katsuno, Y., & Derynck, R. (2021) · Developmental Cell · doi:10.1016/j.devcel.2021.02.028 · Cited by 187
Self-citationEngaging plasticity: Differentiation therapy in solid tumors
Bar-Hai, N., & Ishay-Ronen, D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.944773 · Cited by 35
Metadata
- Authors
- Katsuno, Y., Meyer, D. S., Zhang, Z., Shokat, K. M., Akhurst, R. J., Miyazono, K., & Derynck, R.
- Venue
- Science Signaling
- Published
- 2019-02-26
- Volume
- 12
- Issue
- 570
- ISSN
- 1937-9145 (ISSN-L)
- 1945-0877
- OpenAlex
- W2917523920
- Cited by
- 220
- References
- 14
- FWCI
- 10.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.